title: Interaction between serotonin uptake inhibitors and alpha-2 adrenergic heteroreceptors in the rat hypothalamus.
abstract: The effectiveness of presynaptic receptor agonists to inhibit the electrically evoked release of [3H]monoamines from brain slices is attenuated in the presence of blockade of neuronal uptake for the serotonin (5-HT) and the norepinephrine (NE) systems. There is controversy, however, as to the existence of a functional link between the presynaptic receptors and the neuronal uptake carriers. An alternative hypothesis involves competition for the presynaptic receptor sites between the exogenous agonist and the released neurotransmitter. In order to examine the proposed functional interaction, we studied the alpha-2 adrenoceptor-mediated inhibition of the electrically evoked release of [3H]-5-HT from slices of the rat hypothalamus, a model in which endogenous NE does not activate the alpha-2 heteroreceptors located on 5-HT terminals. The inhibitors of 5-HT uptake, citalopram (0.01-1 microM) and paroxetine (1 microM), which by themselves did not modify [3H]-5-HT release, antagonized the inhibition of [3H]-5-HT overflow produced by UK 14.304, an alpha-2 adrenoceptor agonist. The inhibition of the electrically evoked release of [3H]-5-HT by exogenous NE (0.1-1 microM) was also attenuated in the presence of citalopram. In contrast, citalopram did not modify the electrically evoked release of [3H]-NE or the inhibition of [3H]-NE release mediated by UK 14.304. When the 5-HT autoreceptor was blocked by cyanopindolol, the inhibitory effect of UK 14.304 on [3H]-5-HT release was unaltered in the presence of citalopram.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Biology, Synthélabo Recherche, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Blier
authors.forename: A M
authors.initials: AM
authors.lastname: Galzin
authors.forename: S Z
authors.initials: SZ
authors.lastname: Langer
mesh_terms: D000818:Animals; D000068438:Brimonidine Tartrate; D015283:Citalopram / Q000494:pharmacology*; D010134:Fenclonine / Q000494:pharmacology; D007031:Hypothalamus / Q000187:drug effects*; D066298:In Vitro Techniques; D008297:Male; D009638:Norepinephrine / Q000494:pharmacology; D017374:Paroxetine; D010880:Piperidines / Q000494:pharmacology*; D011810:Quinoxalines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects*; D011985:Receptors, Serotonin / Q000187:drug effects; D012701:Serotonin / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000494:pharmacology*
chemical_list: D010880:Piperidines; D011810:Quinoxalines; D011942:Receptors, Adrenergic, alpha; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D015283:Citalopram; D012701:Serotonin; D017374:Paroxetine; D000068438:Brimonidine Tartrate; D010134:Fenclonine; D009638:Norepinephrine